Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.8% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3201
Gain Therapeutics
GANX
$92.6M
| $169K | ﹤0.01% |
+94,000
| New | +$174K |
|
3202
Urban One Class D
UONEK
$24.1M
| $166K | ﹤0.01% |
26,021
+1,310
| +5% | +$7.84K |
|
|
TAOX
3203
Tao Synergies Inc
TAOX
$26M
| $165K | ﹤0.01% |
+21,000
| New | +$59.9K |
|
3204
Rallybio
RLYB
$88.1M
| $164K | ﹤0.01% |
60,629
+11,066
| +22% | +$29.3K |
|
3205
Toro Corp
TORO
$195M
| $164K | ﹤0.01% |
75,000
+7,500
| +11% | +$15.1K |
|
3206
SkinHealth Systems
SKIN
$84.2M
| $163K | ﹤0.01% |
85,591
+20,300
| +31% | +$28.6K |
|
3207
Ebang International Holdings
EBON
$12.3M
| $162K | ﹤0.01% |
49,213
-500
| -1% | -$1.81K |
|
|
LND
3208
BrasilAgro
LND
$348M
| $162K | ﹤0.01% |
42,400
+4,400
| +12% | +$16.8K |
|
3209
American Shared Hospital Services
AMS
$10.2M
| $161K | ﹤0.01% |
66,700
-3,200
| -5% | -$8.29K |
|
|
LFT
3210
Lument Finance Trust
LFT
$36.5M
| $158K | ﹤0.01% |
71,283
-148,817
| -68% | -$375K |
|
|
CODX
3211
Co-Diagnostics
CODX
$5.49M
| $157K | ﹤0.01% |
18,701
+357
| +2% | +$3.34K |
|
|
GGRP
3212
Glimpse Group
GGRP
$19.5M
| $157K | ﹤0.01% |
115,458
+25,666
| +29% | +$32.8K |
|
|
VSTA
3213
DELISTED
Vasta Platform
VSTA
| $156K | ﹤0.01% |
36,600
+15,500
| +73% | +$67.6K |
|
3214
NanoViricides
NNVC
$34.9M
| $156K | ﹤0.01% |
111,400
+5,600
| +5% | +$7.65K |
|
|
ORKA
3215
Oruka Therapeutics
ORKA
$7.11B
| $156K | ﹤0.01% |
13,900
-21,900
| -61% | -$228K |
|
3216
GrowGeneration
GRWG
$105M
| $155K | ﹤0.01% |
166,110
-94,076
| -36% | -$100K |
|
3217
CPS Technologies
CPSH
$83M
| $155K | ﹤0.01% |
55,958
+1,000
| +2% | +$2.13K |
|
3218
Cohen & Co
COHN
$38.7M
| $155K | ﹤0.01% |
15,600
-2,731
| -15% | -$22.4K |
|
3219
Harte-Hanks
HHS
$18.6M
| $154K | ﹤0.01% |
38,800
-10,484
| -21% | -$47K |
|
|
NBP
3220
NovaBridge Biosciences American Depositary Shares
NBP
$216M
| $154K | ﹤0.01% |
63,700
-100
| -0.2% | -$136 |
|
|
CMCM
3221
Cheetah Mobile
CMCM
$93.7M
| $154K | ﹤0.01% |
32,845
-200
| -0.6% | -$806 |
|
3222
SIFCO Industries
SIF
$124M
| $153K | ﹤0.01% |
40,934
-5,762
| -12% | -$17.5K |
|
3223
Broadway Financial
BYFC
$105M
| $153K | ﹤0.01% |
21,049
+200
| +1% | +$1.28K |
|
|
VTYX
3224
DELISTED
Ventyx Biosciences
VTYX
| $153K | ﹤0.01% |
71,300
-945,089
| -93% | -$1.53M |
|
3225
Arts-Way Manufacturing Co
ARTW
$13.3M
| $152K | ﹤0.01% |
66,274
+6,400
| +11% | +$11.2K |
|
Similar funds
Jim Simons's Q2 2025 Portfolio in Review
As of Q2 2025, Jim Simons held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Jim Simons added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Jim Simons's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Jim Simons fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Jim Simons's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Jim Simons opened 612 new positions and closed 496 in Q2 2025.
- Jim Simons's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.